{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:19:18Z","timestamp":1792189158433,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                      pneumonia (PCP)-related risk factors among patients with solid tumors are not completely defined. Thus, we aimed to characterize PCP cases with underlying solid tumors, to highlight the factors contributing to its development besides the prolonged use of moderate-to-high dose corticosteroids.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the medical records of patients with solid tumors diagnosed with PCP between 2006 and 2018 at a cancer center in Tokyo, Japan. Demographic and clinical data were collected, which included malignancy types, total lymphocyte count, coexisting pulmonary disease, chemotherapy, radiation therapy, corticosteroid use, and PCP-attributable mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty cases of PCP with solid tumors were documented in 151,718 patients and 788,914 patient-years. Lung cancer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096, 30%) was the most common underlying tumor, followed by breast cancer (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093, 15%). Only six (30%) patients were taking a dosage of \u226520\u2009mg prednisone equivalents daily for \u22654\u2009weeks from the onset of PCP. Among the remaining 14 patients, seven (50%) had coexisting pulmonary diseases, 10 (71%) had received chemotherapy within 90\u2009days prior to PCP diagnosis, seven (50%) had undergone chest radiation therapy before PCP diagnosis, seven (50%) had received only intermittent corticosteroids, and one (7%) received no corticosteroids. Mortality attributable to PCP was 40%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than half of the patients were not taking a dosage of \u226520\u2009mg prednisone equivalents daily for \u22654\u2009weeks. Multiple other factors (e.g., lymphocytopenia, radiation to chest) may have potentially contributed to PCP in patients with solid tumors in a composite manner. We need to establish a method for estimating the likelihood of PCP taking multiple factors into account in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08727-2","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:03:14Z","timestamp":1630656194000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Clinical characteristics and risk factors\u00a0associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records\u00a0of a large cancer center"],"prefix":"10.1186","volume":"21","author":[{"given":"Koichi","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-6564","authenticated-orcid":false,"given":"Sohei","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hoashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ohkushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"1242","key":"8727_CR1","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.amjmed.2014.07.010","volume":"127","author":"P Fillatre","year":"2014","unstructured":"Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127(1242):e11\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2014.07.010.","journal-title":"Am J Med"},{"issue":"3","key":"8727_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/00365548.2013.865142","volume":"46","author":"F Roblot","year":"2014","unstructured":"Roblot F, Le Moal G, Kauffmann-Lacroix C, Bastides F, Boutoille D, Verdon R, et al. Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment. Scand J Infect Dis. 2014;46(3):210\u20134. https:\/\/doi.org\/10.3109\/00365548.2013.865142.","journal-title":"Scand J Infect Dis"},{"issue":"30","key":"8727_CR3","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043\u201354. https:\/\/doi.org\/10.1200\/JCO.18.00374.","journal-title":"J Clin Oncol"},{"key":"8727_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer-Related Infections. National Comprehensive Cancer Network. Version 1. 2020 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. Accessed on Oct 18, 2020."},{"issue":"6","key":"8727_CR5","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","volume":"100","author":"AY Classen","year":"2021","unstructured":"Classen AY, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff LD, et al. Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the infectious diseases working Party of the German Society of hematology and medical oncology (AGIHO\/DGHO). Ann Hematol. 2021;100(6):1603\u201320. https:\/\/doi.org\/10.1007\/s00277-021-04452-9.","journal-title":"Ann Hematol"},{"issue":"2","key":"8727_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-015-3573-2","volume":"154","author":"AG Waks","year":"2015","unstructured":"Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, et al. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015;154(2):359\u201367. https:\/\/doi.org\/10.1007\/s10549-015-3573-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"8727_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1078155211412991","volume":"18","author":"S Kim","year":"2012","unstructured":"Kim S, Bordeleau L, Tannock IF, Rotstein C. A fatal case of pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab. J Oncol Pharm Pract. 2012;18(2):293\u20135. https:\/\/doi.org\/10.1177\/1078155211412991.","journal-title":"J Oncol Pharm Pract"},{"key":"8727_CR8","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.21873\/anticanres.11277","volume":"36","author":"A Ray","year":"2016","unstructured":"Ray A, Khong B, Khong HT. A case report of Pneumocystis jiroveci pneumonia in a patient with metastatic breast cancer. Anticancer Res. 2016;36:6673\u20136. https:\/\/doi.org\/10.21873\/anticanres.11277.","journal-title":"Anticancer Res"},{"issue":"8","key":"8727_CR9","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1200\/JCO.2013.49.9277","volume":"33","author":"MC Loron","year":"2015","unstructured":"Loron MC, Grange S, Guerrot D, Di Fiore F, Freguin C, Hanoy M, et al. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J Clin Oncol. 2015;33(8):e45\u20137. https:\/\/doi.org\/10.1200\/JCO.2013.49.9277.","journal-title":"J Clin Oncol"},{"issue":"5","key":"8727_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/jjco\/hyt019","volume":"43","author":"Y Saito","year":"2013","unstructured":"Saito Y, Nagayama M, Miura Y, Ogushi S, Suzuki Y, Noro R, et al. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol. 2013;43(5):559\u201362. https:\/\/doi.org\/10.1093\/jjco\/hyt019.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"8727_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/MPA.0b013e31825486f8","volume":"42","author":"J P\u00e9ron","year":"2013","unstructured":"P\u00e9ron J, Derbel O, Penet A-S, Stella M, M\u00e9eus P, Orlandini F, et al. Concomitant occurrence of pulmonary invasive aspergillosis and pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma. Pancreas. 2013;42(1):178\u201380. https:\/\/doi.org\/10.1097\/MPA.0b013e31825486f8.","journal-title":"Pancreas."},{"issue":"1","key":"8727_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3109\/10428194.2014.911861","volume":"56","author":"SM Lingaratnam","year":"2015","unstructured":"Lingaratnam SM, Slavin MA, Thursky KA, Teh BW, Haeusler GM, Seymour JF, et al. Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. Leuk Lymphoma. 2015;56(1):157\u201362. https:\/\/doi.org\/10.3109\/10428194.2014.911861.","journal-title":"Leuk Lymphoma"},{"issue":"1B","key":"8727_CR13","first-page":"651","volume":"25","author":"V Barbounis","year":"2005","unstructured":"Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res. 2005;25(1B):651\u20135.","journal-title":"Anticancer Res"},{"issue":"1","key":"8727_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41598-019-38618-3","volume":"9","author":"EH Lee","year":"2019","unstructured":"Lee EH, Kim EY, Lee SH, Roh YH, Leem AY, Song JH, et al. Risk factors and clinical characteristics of pneumocystis jirovecii pneumonia in lung cancer. Sci Rep. 2019;9(1):2094. https:\/\/doi.org\/10.1038\/s41598-019-38618-3.","journal-title":"Sci Rep"},{"issue":"28","key":"8727_CR15","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour S, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240\u201361. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789.","journal-title":"J Clin Oncol"},{"key":"8727_CR16","doi-asserted-by":"publisher","first-page":"2464791","DOI":"10.1155\/2016\/2464791","volume":"2016","author":"ML Calero-Bernal","year":"2016","unstructured":"Calero-Bernal ML, Martin-Garrido I, Donazar-Ezcurra M, Limper AH, Carmona EM. Intermittent courses of corticosteroids also present a risk for pneumocystis pneumonia in non-HIV patients. Can Respir J. 2016;2016:2464791\u20137. https:\/\/doi.org\/10.1155\/2016\/2464791.","journal-title":"Can Respir J"},{"issue":"8713","key":"8727_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/0140-6736(90)92008-6","volume":"336","author":"AE Wakefield","year":"1990","unstructured":"Wakefield AE, Pixley FJ, Banerji S, Sinclair K, Miller RF, Moxon ER, et al. Detection of pneumocystis carinii with DNA amplification. Lancet. 1990;336(8713):451\u20133. https:\/\/doi.org\/10.1016\/0140-6736(90)92008-6.","journal-title":"Lancet."},{"issue":"7","key":"8727_CR18","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1469-0691.2010.03452.x","volume":"17","author":"J Held","year":"2011","unstructured":"Held J, Wagner D. \u03b2-D-glucan kinetics for the assessment of treatment response in pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2011;17(7):1118\u201322. https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03452.x.","journal-title":"Clin Microbiol Infect"},{"key":"8727_CR19","doi-asserted-by":"publisher","first-page":"ofy296","DOI":"10.1093\/ofid\/ofy296","volume":"5","author":"A Szyszkowitz","year":"2018","unstructured":"Szyszkowitz A, Zurl C, Herzeg A, Berger A, Gemes G, Mitteregger M, et al. Serum 1,3-Beta-D-Glucan values during and after laparoscopic and open intestinal surgery. Open Forum Infect Dis. 2018;5:ofy296. https:\/\/doi.org\/10.1093\/ofid\/ofy296.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"8727_CR20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321. https:\/\/doi.org\/10.1086\/588660.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"8727_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. https:\/\/doi.org\/10.1186\/1710-1492-9-30.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"8727_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1378\/chest.118.3.704","volume":"118","author":"NG Mansharamani","year":"2000","unstructured":"Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118(3):704\u201311. https:\/\/doi.org\/10.1378\/chest.118.3.704.","journal-title":"Chest."},{"issue":"1","key":"8727_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4065\/71.1.5","volume":"71","author":"SH Yale","year":"1996","unstructured":"Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5\u201313. https:\/\/doi.org\/10.4065\/71.1.5.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"8727_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.7326\/0003-4819-100-5-663","volume":"100","author":"JA Kovacs","year":"1984","unstructured":"Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100(5):663\u201371. https:\/\/doi.org\/10.7326\/0003-4819-100-5-663.","journal-title":"Ann Intern Med"},{"issue":"4","key":"8727_CR25","doi-asserted-by":"publisher","first-page":"e0250611","DOI":"10.1371\/journal.pone.0250611","volume":"16","author":"M Assal","year":"2021","unstructured":"Assal M, Lambert J, Chow-Chine L, Bisbal M, Servan L, Gonzalez F, et al. Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with pneumocystis jirovecii pneumonia: a propensity score analysis. PLoS One. 2021;16(4):e0250611. https:\/\/doi.org\/10.1371\/journal.pone.0250611.","journal-title":"PLoS One"},{"issue":"6","key":"8727_CR26","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jama.1992.03480060078034","volume":"267","author":"KA Sepkowitz","year":"1992","unstructured":"Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267(6):832\u20137. https:\/\/doi.org\/10.1001\/jama.1992.03480060078034.","journal-title":"JAMA."},{"issue":"6","key":"8727_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10096-006-0149-4","volume":"25","author":"HA Torres","year":"2006","unstructured":"Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006;25(6):382\u20138. https:\/\/doi.org\/10.1007\/s10096-006-0149-4.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"8727_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","volume":"11","author":"AE Stuck","year":"1989","unstructured":"Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954\u201363. https:\/\/doi.org\/10.1093\/clinids\/11.6.954.","journal-title":"Rev Infect Dis"},{"issue":"18","key":"8727_CR29","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1056\/NEJMc070728","volume":"357","author":"M Harigai","year":"2007","unstructured":"Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia under anti-tumor necrosis factor therapy (PAT) study group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357(18):1874\u20136. https:\/\/doi.org\/10.1056\/NEJMc070728.","journal-title":"N Engl J Med"},{"issue":"2","key":"8727_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1440-1843.2008.01457.x","volume":"14","author":"T Fujisawa","year":"2009","unstructured":"Fujisawa T, Suda T, Matsuda H, Inui N, Nakamura Y, Sato J, et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology. 2009;14(2):203\u20139. https:\/\/doi.org\/10.1111\/j.1440-1843.2008.01457.x.","journal-title":"Respirology."},{"issue":"7","key":"8727_CR31","doi-asserted-by":"publisher","first-page":"e00286","DOI":"10.1128\/JCM.00286-18","volume":"56","author":"K Dichtl","year":"2018","unstructured":"Dichtl K, Seybold U, Wagener J. Evaluation of a turbidimetric \u03b2-D-glucan test for detection of pneumocystis jirovecii pneumonia. J Clin Microbiol. 2018;56(7):e00286\u201318. https:\/\/doi.org\/10.1128\/JCM.00286-18.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"8727_CR32","doi-asserted-by":"publisher","first-page":"e00322","DOI":"10.1128\/JCM.00322-19","volume":"57","author":"T Mercier","year":"2019","unstructured":"Mercier T, Guldentops E, Patteet S, Beuselinck K, Lagrou K, Maertens J. Beta-D-glucan for diagnosing pneumocystis pneumonia: a direct comparison between the Wako \u03b2-glucan assay and the Fungitell assay. J Clin Microbiol. 2019;57(6):e00322\u201319. https:\/\/doi.org\/10.1128\/JCM.00322-19.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08727-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08727-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08727-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:05:14Z","timestamp":1630656314000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08727-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8727"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08727-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Cancer Institute Hospital, Japanese Foundation for Cancer Research prior to initiation (approval number: 2019\u20131018). All procedures were in accordance with the 1964 Declaration of Helsinki and its later amendments or with comparable ethical standards. Informed consent for this retrospective, noninvasive study was not required by the local ethics committee. The local ethics committee permitted to access the raw data from the hospital database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SH has received honoraria from MSD, Shionogi, Astellas, BD, Beckman Coulter Diagnostics, Sumitomo Dainippon Pharma, and Meiji; has served in a consultancy<b>\/<\/b>advisory role for FUJIFILM Toyama Chemical; and has received research funding from MSD, outside the submitted work. BH has received honoraria from Janssen Pharmaceutica, outside the submitted work. DO has received Honoraria from Sumitomo Dainippon, outside the submitted work. All other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"987"}}